CDK inhibitors in cancer therapy: what is next?

The pursuit for drugs that inhibit cyclin-dependent kinases (CDKs) has been an intense area of research for more than 15 years. The first-generation inhibitors, Flavopiridol and CY-202, are in late-stage clinical trials, but so far have demonstrated only modest activity. Several second-generation in...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Trends in pharmacological sciences (Regular ed.) 2008-01, Vol.29 (1), p.16-21
Hauptverfasser:	Malumbres, Marcos, Pevarello, Paolo, Barbacid, Mariano, Bischoff, James R
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced Basic Science Animals Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Cell Cycle - drug effects Clinical Trials as Topic Cyclin-Dependent Kinases - antagonists & inhibitors Drug Delivery Systems Enzyme Inhibitors - pharmacology Enzyme Inhibitors - therapeutic use Humans Neoplasms - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!